News Posts List
Lpath Signs Collaboration and License Agreement With Provista Diagnostics to Develop Cancer Diagnostics
03/07/2013
The company is developing three drug candidates: iSONEP™ is being studied in a Phase 2 trial in wet AMD patients; ASONEP™ is being studied in a Phase 2 trial in renal cell carcinoma patients; and Lpathomab is a preclinical drug candidate that holds promise in pain, neurotrauma, and other diseases.
Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
03/07/2013
Preclinical studies have suggested that sunitinib accelerates metastases in animals, ascribing this to inhibition of the vascular endothelial growth factor receptor or the tumor’s adaptation.
Join us for a World Kidney Day Celebration!
03/07/2013
Live day-long kidney health web chat at KidneyCancer.org
Panel to Review AVEO/ALPMY's Drug
03/07/2013
AVEO Pharmaceuticals, Inc. (AVEO) and Astellas Pharma, Inc. (ALPMY) recently announced that the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will review tivozanib on May 2, 2013.
India Appeals Body Rejects Bayer's Nexavar Plea
03/05/2013
India's patent appeals body Monday rejected Bayer AG's (BAYRY, BAYN.XE) plea to stop a local company from manufacturing and selling a generic version of its cancer drug Nexavar, a ruling that has wider implications for multinational drug makers operating in the South Asian nation.
Kidney Disease Caused By High-Fat Diets Tackled By Grape Seed And Skin Extract
03/05/2013
New insight into grape seed extract as a therapeutic and preventative measure to fight obesity-induced kidney damage is presented in a new study.
Argos Therapeutics Validates Durability of AGS-003 Induced Immune Response
03/05/2013
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced it has validated the durability of the immune response for metastatic renal cell carcinoma (mRCC) patients treated with AGS-003.
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma
03/05/2013
The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral tyrosine kinase inhibitors (TKIs) is associated with poorer outcome as compared with patients without bone involvement.
Novartis CEO: We need to re-think the blockbuster
03/05/2013
Big Pharma companies have hit a wall chasing billion-dollar drugs. Novartis CEO Joseph Jimenez outlines a new paradigm for blockbuster medications.
Fully funded DPhil (PhD) studentships are available from the Ludwig Institute for Cancer Research
03/04/2013
The studentship benefits include a bursary of £18,000 pa, University & College fees (home/EU rate only) and the opportunity to work in a cutting edge research environment.
News Feed